NCT04762511 - A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 2, 2021

Primary Completion Date

May 26, 2021

Study Completion Date

May 26, 2021

Conditions

Herpes Simplex

Interventions

BIOLOGICAL

Lower dose formulation of HSV vaccine (GSK4108771A)

2 doses of the lower dose formulation of HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.

BIOLOGICAL

Low dose formulation of HSV vaccine (GSK4108771A)

2 doses of the low dose formulation of HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.

BIOLOGICAL

Medium dose formulation of HSV vaccine (GSK4108771A)

2 doses of the medium dose formulation of HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.

BIOLOGICAL

High dose formulation of HSV vaccine (GSK4108771A)

2 doses of the high dose formulation of the HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.

DRUG

Placebo (saline)

2 doses of placebo (saline) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.

Trial Locations (2)

14609

GSK Investigational Site, Rochester

66219

GSK Investigational Site, Lenexa